{'fraction_non_alphanumeric': 0.053742802303262956, 'fraction_numerical': 0.05950095969289827, 'mean_word_length': 5.141176470588236, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Induction and clinical utilization of lymphokine‐activated killer cells in patients with gastrointestinal tract cancers

Abstract In 18 patients with cancers of the gastrointestinal tract, lymphokine‐activated killer (LAK) cell activity was studied and compared with that of healthy subjects. After cultivation with 103 iu/mL of recombinant interleukin‐2, the cytotoxicity of patients' lymphoid cells was increased from 13.6 ±6.8% to 76.2 ±19.5% against Daudi cells and from 12.8 ±8.1% to 76.2 ±19.5% against K‐562 cells.